Noxopharm White Paper

NOXOPHARM L IMITED White Paper 12 Veyonda® – LuPIN program continued LuPIN-1 Phase 1b/2a study of Veyonda combined with Lu-PSMA, a radionuclide for the management of advanced prostate cancer that has stopped responding to standard therapy The LuPIN study was an investigator-initiated Phase 1b/2a trial at St Vincent’s Hospital in Sydney involving 56 men with end-stage metastatic castrate-resistant prostate cancer (mCRPC) whose disease had progressed despite 3 lines of previous treatment with other prostate cancer therapies. The study is now complete and data was presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, a major medical conference, in Feb 2021. Results were: • High PSA response rate. 61% had a PSA reduction > 50% and 86% had any PSA reduction. PSA in cancer therapy is an indicator of disease activity. • 53% of men suffering moderate to strong pain associated with cancer reported a significant reduction in pain. • Progression free survival (PFS) of 7.5 months, and 5 of 56 men have not progressed. • 46% of men were able to complete the full 6 cycles of treatment without cancer progression. • Median overall survival (mOS) of 19.7 months versus a 4.5-month median overall survival for a comparable patient population receiving standard therapy. A mOS of 19.7 months is particularly of note as the patients recruited had end-stage metastatic disease and their disease had progress despite a number of prior treatment pathways. There are multiple studies on similar patient populations that were treated with 177 Lu-PSMA-617 as a sole treatment; the LuPIN combination treatment incorporating Veyonda compares favourably with these studies. Study Treatment Patient Number Median Overall Survival (months) LuPIN Veyonda + Lu-PSMA 56 19.7 WARMTH Lu-PSMA 319 11.6 VISION Lu-PSMA 551 15.3